Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 196Myelodysplastic Syndromes 128Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Leukemia, Lymphocytic, Chronic, B-Cell 102Leukemia 102Lymphoma 86Multiple Myeloma 81Lymphoma, Non-Hodgkin 80Hematologic Neoplasms 65Leukemia, Myelogenous, Chronic, BCR-ABL Positive 62Hodgkin Disease 62Recurrence 52Lymphoma, B-Cell 40Lymphoma, Mantle-Cell 39Myeloproliferative Disorders 36Lymphoma, Follicular 35Melanoma 34Lymphoma, Large B-Cell, Diffuse 31Burkitt Lymphoma 31Graft vs Host Disease 28Neoplasms, Plasma Cell 24Primary Myelofibrosis 23Ovarian Neoplasms 23Lymphoma, B-Cell, Marginal Zone 23Anemia, Refractory, with Excess of Blasts 21Leukemia, Myelomonocytic, Chronic 20Leukemia, Biphenotypic, Acute 17Lymphoma, T-Cell 16Neuroblastoma 15Neoplasms 14

Interventions

Cisplatin 28Pemetrexed 24pembrolizumab 12Nivolumab 10Carboplatin 9atezolizumab 7Gemcitabine 7Cyclophosphamide 7durvalumab 6Drug Therapy 6sodium thiosulfate 5Radiotherapy, Intensity-Modulated 5tremelimumab 4aldesleukin 4Radiotherapy 4Interleukin-2 4sargramostim 3Vinorelbine 3Platinum 3Photochemotherapy 3Ipilimumab 3Doxorubicin 3Dihematoporphyrin Ether 3Chemotherapy, Adjuvant 3Cerebral Decortication 3vatalanib 2regorafenib 2niraparib 2lenvatinib 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mesothelioma, Malignant × fludarabine × Clear all
NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

University Health Network, Toronto

Phase 1/2 Completed
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡